[ad_1]
Australia-based decision support software developer Eyetelligence and UAE-based Alliance Care Technologies (ACT) have announced a strategic partnership to bring transformative AI ophthalmology solutions to the UAE market.
Preferred partner agreement signed at Precision Med Expo to provide independent and hospital clinics with glaucoma detection support, referral diabetic retinopathy screening support and grading, and screening for neovascular age-related macular degeneration (nAMD) Check support.
The signing ceremony was held at the Alliance Care Technologies booth at Precision Med Expo in Dubai, witnessed by Mounir Sankary, Deputy Consul General of Australia in Dubai. Attendees representing Eyetelligence included Founder Professor Mingguang He, MD; CEO Rainer Grote and Chief Strategy Officer Jason Sun.
Alliance Care Technologies is represented by Founder and CEO Michele Tarnow and Chief Medical Officer Aaron Han, MD, PhD.
Advanced technology
The Eyetelligence team presented this advanced technology to the UAE market at the Precision Med Summit. The launch event included live presentations by Mingguang (Ming) He, MD, PhD, Professor of Ophthalmic Epidemiology, Melbourne Medical School, Faculty of Medicine, Dental and Health Sciences, University of Melbourne; and Head of Ophthalmic Epidemiology, Australian Center for Eye Research.
Professor Ming is a global expert in the clinical application of artificial intelligence in medicine and the founder of Eyetelligence and Eyerising, two Australian international medical technology companies, which brought Dr Ming’s artificial intelligence technology and phototherapy technology to the market.
Professor Ming said: “Artificial intelligence has evolved from computer software in the laboratory to clinical adaptation in many image-driven practices, including ophthalmology. Combining the availability of large datasets and dramatically increased computing power, deep learning algorithms (DLA) have created Unprecedented opportunity to significantly improve the accuracy of automated detection and diagnosis of eye diseases.
manual input
“This development will enable eye care to be less dependent on human input, thereby increasing accessibility, efficiency and cost-effectiveness, making eye disease diagnosis and management faster, cheaper and more consistent.”
Eyetelligence Assure is an advanced artificial intelligence software solution that analyzes retinal image signatures for three major blinding eye conditions: glaucoma, referable diabetic retinopathy, and referable neovascular age-related macular degeneration.
Backed by peer-reviewed publications and journals, Eyetelligence’s deep learning technology is designed to empower clinicians to make more informed clinical decisions with speed, accuracy and confidence to ensure optimal health outcomes for patients. Also available is Eyetelligence Microvascular, a non-invasive platform that detects early signs of cardiovascular disease based on microvascular profiles. Eyerising brings to market Eyerising Myproclear, which controls the development of myopia in children with the world’s first non-invasive at-home device for myopia control.
Demand
“We anticipate strong demand for this technology in the region,” said Michele Tarnow, CEO of Alliance Care Technologies. “Our partnership with Eyetelligence and Eyerising in the Gulf will be independent and based on The hospital’s clinic provides glaucoma detection support, referral diabetic retinopathy screening support and grading, and neovascular age-related macular degeneration (nAMD) screening support. We are delighted that Professor Ming can personally share his expertise and advanced technical solutions.”
Mounir Sankary, Deputy Consul General of Dubai and Austrade Commissioner for Trade, said: “We at the Australian Trade and Investment Commission (Austrade) are delighted to see this partnership agreement between Eyetelligence and Alliance Care Technologies, which will utilize advanced artificial intelligence capabilities for Quality preventative health measures for the people of the UAE. These are exactly the kind of partnerships we would love to see – a shared passion and expertise between Australia and the UAE, with a focus on innovation and reducing the burden of ill health in the community.”
Professor Ming, along with members of the Eyetelligence and Alliance Care Technologies teams, demonstrated this breakthrough technology at the ACT booth during the Precision Med Expo conference. — trade arab news agency
[ad_2]
Source link